Compare FCPT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FCPT | PHVS |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.4B |
| IPO Year | 2015 | 2020 |
| Metric | FCPT | PHVS |
|---|---|---|
| Price | $24.18 | $37.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | $28.00 | ★ $41.82 |
| AVG Volume (30 Days) | 553.9K | ★ 907.4K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.79% | N/A |
| EPS Growth | ★ 1.87 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $294,132,000.00 | N/A |
| Revenue This Year | $6.66 | N/A |
| Revenue Next Year | $8.28 | N/A |
| P/E Ratio | $44.58 | ★ N/A |
| Revenue Growth | ★ 9.72 | N/A |
| 52 Week Low | $22.78 | $20.65 |
| 52 Week High | $26.86 | $43.25 |
| Indicator | FCPT | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 35.21 | 61.26 |
| Support Level | $24.06 | $24.95 |
| Resistance Level | $25.66 | N/A |
| Average True Range (ATR) | 0.31 | 1.87 |
| MACD | -0.07 | 0.13 |
| Stochastic Oscillator | 4.25 | 42.70 |
Four Corners Property Trust Inc is a real estate investment trust predominantly engaged in the ownership, acquisition and leasing of restaurant and retail properties. The company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries. The firm operates through two segments namely, real estate operations and restaurant operations. The real estate operations segment consists of rental revenues generated by leasing restaurant and retail properties to tenants. The restaurant operations segment is conducted through a taxable REIT subsidiary (TRS) and consists of Kerrow Restaurant Operating Business. The firm generates majority of the revenue from the real estate operations segment.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.